exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088102 RNA Name: hsa-miR-3163 RNA Type: miRNA Chromosome: chr11 Starnd: - Coordinate: Start Site(bp): 66934476 End Site(bp): 66934497 External Links: hsa-miR-3163

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: NA miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000642 chr15 80390757 80415142 + hsa_circ_0000643 chr15 80412669 80415142 + hsa_circ_0001414 chr4 56277780 56284152 + hsa_circ_0000106 chr1 111690263 111703918 + hsa_circ_0000552 chr14 71880664 71948928 + hsa_circ_0000799 chr17 65941524 65972074 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC007038.1 chr2 210028417 210029156 + AC010980.2 chr2 222317242 222318653 - AC021078.1 chr5 149494314 149504670 - AC022167.2 chr16 8848105 8860456 + AC051619.7 chr15 45200325 45200632 - AC092718.4 chr16 81030770 81031485 + AC243964.3 chr19 44631573 44725217 - DLEU2 chr13 49956670 50125720 - DSCAM-AS1 chr21 40383083 40385358 + FGD5-AS1 chr3 14920347 14948424 - GABPB1-AS1 chr15 50354959 50372202 + HCG11 chr6 26521709 26527404 + LINC00662 chr19 27681072 27794005 - MALAT1 chr11 65497688 65506516 + MEG8 chr14 100894770 101038859 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG1 chr11 62851984 62855953 - SNHG5 chr6 85650491 85678932 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.